Federal Grant Award Summary

The University of Washington received a $672,701 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) on February 15, 2026, with a completion date of November 30, 2030. This research initiative will implement HIV screening and prevention services within low-barrier office-based opioid treatment (OBOT) programs at Harborview Medical Center in Seattle, Washington, supporting the federal "End the HIV Epidemic" initiative targeting a 90% reduction in HIV incidence by 2030. The project specifically addresses the integration of HIV testing, pre-exposure prophylaxis (PrEP)—including the newly available twice-yearly injectable formulation—and medications for opioid use disorder (MOUD) such as buprenorphine within primary care-integrated treatment settings serving people who use drugs.

Through this award, the University of Washington will conduct mixed-methods research to assess and improve the HIV testing and prevention cascade among patients in four co-located OBOT programs. Deliverables include characterization of current HIV prevention practices, evaluation of patient preferences for PrEP modalities and health services, and implementation strategies to increase uptake of HIV screening and prevention services in office-based treatment settings. The research addresses a critical gap in HIV prevention infrastructure by examining the feasibility and effectiveness of integrating comprehensive HIV care within evolving substance use treatment delivery systems that increasingly serve patients with polysubstance use patterns.